首页> 外文OA文献 >Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer

【2h】

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer

机译：雌激素受体阳性或三阴性乳腺癌的妇女中，SeviterOk，一种选择性Cyp17裂解酶和雄激素受体抑制剂的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Aditya Bardia; Ayca Gucalp; Noashir DaCosta; Nashat Gabrail; Michael Danso; Haythem Ali; Kimberly L. Blackwell; Lisa A. Carey; Joel R. Eisner; Edwina S. Baskin-Bey; Tiffany A. Traina;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer [J] . Bardia Aditya, Gucalp Ayca, DaCosta Noashir, Breast cancer research and treatment. . 2018,第1期

机译：雌激素受体阳性或三阴性乳腺癌的妇女中，SeviterOk，一种选择性Cyp17裂解酶和雄激素受体抑制剂的研究
2. Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer [J] . Gupta Shilpa, Nordquist Luke T., Fleming Mark T., Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第21期

机译：I阶段研究SeviterOnel，一种选择性CYP17裂解酶和雄激素受体抑制剂，在具有抗阉割前列腺癌的男性中
3. A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer [J] . Peer Cody J., Schmidt Keith T., Kindrick Jessica D., Cancer chemotherapy and pharmacology. . 2019,第4期

机译：口服CYP17裂解酶和雄激素受体抑制剂SeviteroneL中的人口药代动力学分析患者晚期/转移性阉割前列腺癌或乳腺癌患者
4. Estrogen Receptor-Positive Breast Cancer: Traditional Prognostics, Molecular Pathology: A New Breast Cancer Taxonomy and 21st Century Personalized Prognostic and Predictive Assays [C] . Frederick L. Baehner International Symposium on Cancer Metastasis and the Lymphovascular system: Basis for Rational Therapy . 2009

机译：雌激素受体阳性乳腺癌：传统预测，分子病理：新的乳腺癌分类和21世纪个性化预测和预测测定
5. Zna?aj odre?ivanja Androgenih Receptora u Odgovoru Na Hormonsku Terapiju Kod Estrogen Receptor Pozitivnih Pacijenata Sa Karcinomom Dojke =The Significance of Determining the Androgen Receptors in Response to Hormonal Therapy in Estrogen Receptor-Positive [D] . Vidovi?, Vladimir. 2020

机译：雌激素受体阳性乳腺癌阳性患者对雌激素治疗响应雌激素治疗的意义=患有雌性受体阳性荷尔蒙治疗厌氧受体的重要性
6. Phase 1 Study of Seviteronel a Selective CYP17 Lyase and Androgen Receptor Inhibitor in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer [O] . Aditya Bardia, Ayca Gucalp, Noashir DaCosta, -1

机译：Seviteronel（一种选择性的CYP17裂解酶和雄激素受体抑制剂）在具有雌激素受体阳性或三阴性乳腺癌的女性中进行的1期研究
7. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells [O] . Anna R. Michmerhuizen, Benjamin Chandler, Eric Olsen, 2020

机译：SeviteOLEL，一种新型CYP17裂解酶抑制剂和雄激素受体拮抗剂，辐射敏感性AR阳性三重阴性乳腺癌细胞

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅